Ebalzotan

Ebalzotan (NAE-086) is a selective 5-HT1A receptor agonist.[1][2] It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued.[1][2]

Ebalzotan
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
IUPAC name
  • (3R)-N-(propan-2-yl)-3-[propan-2-yl(propyl)amino]-3,4-dihydro-2H-chromene-5-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H30N2O2
Molar mass318.461 g·mol−1
3D model (JSmol)
SMILES
  • O=C(NC(C)C)c2cccc1OC[C@H](N(C(C)C)CCC)Cc12

See also

References
  1. Braish T, Gadamasetti KG (2008). Process chemistry in the pharmaceutical industry, volume 2 challenges in an ever changing climate. Boca Raton: CRC Press. ISBN 978-0-8493-9051-7.
  2. Weaver DF, Nogrady T, Nogrady T (2005). Medicinal chemistry a molecular and biochemical approach. Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-510455-2.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.